



FIG. 1B

21: 2019/02458. 22: 2019/04/17. 43: 2020/05/26
 51: H04L; H04W
 71: SHARP KABUSHIKI KAISHA, FG INNOVATION COMPANY LIMITED
 72: YIN, ZHANPING, NOGAMI, TOSHIZO
 33: US 31: 62/401,782 32: 2016-09-29
54: SYSTEMS AND METHODS FOR DETERMINING FRAME STRUCTURE AND ASSOCIATION TIMING
 00: -

A user equipment (UE) is described. The UE includes a processor. The UE also includes memory in electronic communication with the processor. Instructions stored in the memory are executable to determine a radio frame structure based on a self-contained subframe pattern. The instructions are also executable to receive a downlink data assignment and decode downlink data. The instructions are further executable to determine a hybrid automatic repeat request acknowledgement/negative acknowledgement (HARQ-ACK) feedback timing of the downlink data. The instructions are additionally executable to transmit HARQ-ACK feedback of the downlink data based on the determined HARQ-ACK feedback timing. The instructions are also executable to receive uplink scheduling information. The instructions are further executable to determine an uplink scheduling timing for a scheduled uplink transmission. The instructions are additionally

executable to transmit uplink data in a scheduled subframe.



FIG. 2

21: 2019/02533. 22: 2019/04/23. 43: 2020/05/26
 51: A61K; C07K; G01N
 71: SHANGHAI HENLIUS BIOTECH, INC.
 72: JIANG, WEIDONG, LIN, PEI-HUA, TSENG, CHILING
 33: US 31: 62/414,785 32: 2016-10-30
54: ANTI-PD-L1 ANTIBODIES AND VARIANTS
 00: -

Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.